p53 Isoforms as Cancer Biomarkers and Therapeutic Targets.
Cancers (Basel)
; 14(13)2022 Jun 27.
Article
en En
| MEDLINE
| ID: mdl-35804915
This review aims to summarize the implications of the major isoforms of the tumor suppressor protein p53 in aggressive cancer development. The current knowledge of p53 isoforms, their involvement in cell-signaling pathways, and their interactions with other cellular proteins or factors suggests the existence of an intricate molecular network that regulates their oncogenic function. Moreover, existing literature about the involvement of the p53 isoforms in various cancers leads to the proposition of therapeutic solutions by altering the cellular levels of the p53 isoforms. This review thus summarizes how the major p53 isoforms Δ40p53α/ß/γ, Δ133p53α/ß/γ, and Δ160p53α/ß/γ might have clinical relevance in the diagnosis and effective treatments of cancer.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Idioma:
En
Revista:
Cancers (Basel)
Año:
2022
Tipo del documento:
Article
País de afiliación:
Suecia
Pais de publicación:
Suiza